1-hexadecyl-2-acetyl-glycero-3-phosphocholine and mepivacaine

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with mepivacaine in 1 studies

Compound Research Comparison

Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine)	Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine)	Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine)	Studies (mepivacaine)	Trials (mepivacaine)	Recent Studies (post-2010) (mepivacaine)
9,156	187	552	2,074	495	268

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Church, MK; Petersen, LJ; Skov, PS	1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and mepivacaine

Article	Year
Platelet-activating factor induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade. The Journal of allergy and clinical immunology, 1997, Volume: 99, Issue:5 Topics: Adult; Anesthetics, Local; Basophils; Capsaicin; Dose-Response Relationship, Drug; Female; Histamine Release; Humans; Male; Mast Cells; Mepivacaine; Microdialysis; Middle Aged; Nerve Block; Platelet Activating Factor; Skin	1997

Article

Year

Platelet-activating factor induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade.

The Journal of allergy and clinical immunology, 1997, Volume: 99, Issue:5

Topics: Adult; Anesthetics, Local; Basophils; Capsaicin; Dose-Response Relationship, Drug; Female; Histamine Release; Humans; Male; Mast Cells; Mepivacaine; Microdialysis; Middle Aged; Nerve Block; Platelet Activating Factor; Skin

1997